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Abstract
We have developed a mouse model of atherosclerotic plaque regression in which an atherosclerotic aortic arch from a
hyperlipidemic donor is transplanted into a normolipidemic recipient, resulting in rapid elimination of cholesterol and
monocyte-derived macrophage cells (CD68+) from transplanted vessel walls. To gain a comprehensive view of the
differences in gene expression patterns in macrophages associated with regressing compared with progressing
atherosclerotic plaque, we compared mRNA expression patterns in CD68+ macrophages extracted from plaque in aortic
aches transplanted into normolipidemic or into hyperlipidemic recipients. In CD68+ cells from regressing plaque we
observed that genes associated with the contractile apparatus responsible for cellular movement (e.g. actin and myosin)
were up-regulated whereas genes related to cell adhesion (e.g. cadherins, vinculin) were down-regulated. In addition,
CD68+ cells from regressing plaque were characterized by enhanced expression of genes associated with an anti-
inflammatory M2 macrophage phenotype, including arginase I, CD163 and the C-lectin receptor. Our analysis suggests that
in regressing plaque CD68+ cells preferentially express genes that reduce cellular adhesion, enhance cellular motility, and
overall act to suppress inflammation.
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Introduction
Cardiovascular disease (CVD) is a leading cause of death
worldwide [1]. Absolute risk for CVD rises with age because of the
progression of atherosclerosis [2–5]. This risk could be reduced by
blocking the progression of atherosclerosis or by stimulating
regression of atherosclerotic plaque. Mouse models of atheroscle-
rosis, particularly lines with deficiencies in apoE (apoE2/2) or the
LDL receptor (LDLr2/2) [6–8], have been extensively used to
study atherosclerotic progression and for the identification of
therapeutic approaches to blocking it. However, application of
these models to the study of plaque regression has not been as
actively pursued.
Our laboratory has developed a model of plaque regression in
which an aortic arch segment containing an atherosclerotic plaque
from an apoE2/2 mouse [9] is transplanted to a wild-type (WT)
recipient mouse. This results in the rapid normalization of the
dyslipidemia to which donor plaques are exposed and a rapid
regression of atherosclerosis as judged by a decrease in both plaque
size (i.e., cross sectional intimal area) and the content of monocyte-
derived CD68+ cells (primarily macrophages and macrophage
foam cells). In contrast, when the recipient of the atherosclerotic
arch is an apoE2/2 mouse and the dyslipidemia is not corrected,
progression continues [10–12]. Using laser capture microdissec-
tion to select plaque CD68+ cells under progression and regression
conditions, and qPCR to analyze selected mRNAs, we found large
differences in the expression of specific genes involved in migration
and inflammation [12,13].
In the current study a transcriptome wide analysis of the
macrophage-specific changes associated with plaque regression
was performed. Microarray assays of mRNA from laser captured
CD68+ cells revealed notably different molecular profiles in cells
from plaques in atherosclerotic aortic arches transplanted into
apoE2/2 (progression environment) compared with those from
plaques in arches transplanted into WT recipients (regression
environment).
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Animals and Aortic Transplantation
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee of the New York University School of Medicine
(Permit Number: A3435-01). ApoE2/2 (C57Bl/6) mice were
weaned at 1 month and put on a Western Diet (WD) containing
21% fat and 0.15% cholesterol (Research Diets catalog N
D01022601) for 16 weeks. These mice were then divided into
three groups: a pre-transplant group (n=10) for baseline analyses,
and two transplant groups, a group (n=18) from which aortas
would be transplanted into apoE2/2 recipient mice, and a group
(n=18) from which aortas would be transplanted into wild type
recipient mice. In both cases, recipients were 20 week old male
mice on standard chow diet. The surgeries were performed as
previously described [9]. Briefly, a donor arch was interpositioned
with the abdominal aorta in the recipient mouse and blood flow
was directed through the graft. Recipient mice were maintained
on standard chow diet, and sacrificed at 3 days after transplan-
tation.
Lipid and Lipoprotein Analyses
Blood samples were obtained from the retro-orbital plexus.
Plasma total cholesterol and triglyceride levels were determined by
colorimetric enzymatic assays adapted to 96-well plate formats
(Infinity Total Cholesterol Reagent or Infinity Triglyceride
Reagent, Sigma). Plasma HDL cholesterol was determined by
precipitating non-HDL cholesterol (Wako Diagnostic) and then
assaying the remaining HDL cholesterol by means of the Infinity
Total Cholesterol Reagent.
Lesion Assessment by Immunostaining, Histology and
Morphometry
The pre-transplant and grafted arches were removed, embed-
ded in OCT, and frozen. Serial sections (6 mm thick) were
generated using a cryostat. To detect monocyte-derived cells
(predominately macrophages and macrophage foam cells), sections
were stained for CD68 using rat anti-mouse CD68 (Serotec; 2 mg/
ml). Briefly, sections were incubated for 1 hour at room
temperature with the primary antibody, then with biotinylated
goat anti-rat Ig for 1 hour, followed by incubation with
streptavidin-linked alkaline phosphatase, then developed with
substrate, and finally counterstained with haematoxylin. Negative
controls were performed with an irrelevant primary antibody. To
determine the plaque area, images were digitized, the regions
between the endothelial and the medial smooth muscle cell layers
were traced, and ImagePro Plus software was used to perform the
numerical calculations. A similar approach was taken for the area
stained for CD68 or Oil Red O. At least five sections per vessel
were analyzed and the mean value used as the summary
parameter. The same immunostaining protocol with different
primary antibodies was used in order to detect arginase I (Santa
Cruz Biotechnology, sc-20150) or vinculin (Abcam, ab18058). To
assess the lipid content of the plaques, Oil Red O staining was
performed as previously described [14]. This stain will detect all
neutral lipids, the predominant species being cholesteryl esters and
triglycerides. In plaques, traditionally Oil Red O staining is
thought to reflect the intra and extracellular content of cholesteryl
esters, though it is known that triglycerides are also found in foam
cells to a variable degree.
Laser Capture Microdissection (LCM) and RNA Extraction
To isolate CD68+ cells from plaques, LCM was performed with
the PixCell II (Arcturus Bioscience, Mountain View, CA) as
previously reported [15]. Briefly, 6 mm frozen sections were
dehydrated in ethanol, then twice placed in xylene and air dried.
At 100 mm intervals, sections were immunostained for CD68 and
used as templates for the next five serial sections. RNA was
isolated by the Qiagen RNeasy MicroIsolation kit and treated with
DNase. The concentration of RNA was determined by the
Ribogreen RNA Quantification kit (Molecular Probes), and the
RNA quality verified with the Agilent 2100 Bioanalyzer. Each
microarray RNA sample from laser-captured CD68+ cells
represented a pool of LCM-derived RNA from three aortas, with
an average total RNA per sample of 5 ng. Approximately 2000
CD68+ cells are obtained from each aorta.
RNA Processing and Microarray Analysis
Two rounds of amplification with an ultra low input protocol
(ULI) were used to generate cRNA labeled with Cy5 or Cy3 from
sample RNA (,1–5 ng) generated by LCM [16]. This cRNA was
combined with an equal mass of universal mouse reference RNA
that had been amplified in the same way but labeled with the
opposite fluoro. This mixture was then hybridized to Mouse 3.0
A1 Agilent arrays containing 23427 reporters (not including
control probes, Gene Expression Omnibus (GEO) accession
GPL9733). To avoid bias from the Cy3 and Cy5 labels, fluoro
reverse duplicates were used for all samples (each sample was
labeled independently with Cy3 and Cy5, mixed with labeled
control pool RNA, and each reaction was independently
hybridized to a single microarray, therefore using two arrays per
sample). Data were pre-processed using the standard re-ratio
pipeline in Rosetta Resolver application [17]. Samples were
processed in two independent batches (with four samples from
each of the three groups in each batch). To normalize for batch to
batch variation, samples were first re-ratioed against the pool of all
samples in each batch. Regression-specific genes, as identified by
univariate analysis, were defined by two criteria: Regulated by
regression (Progression vs. Regression ANOVA p,0.05) and not
regulated by transplantation (Progression vs. Baseline control
ANOVA p.0.1). To select genes with stable variance, a final filter
using Resolver error model P,0.05 was applied [17], and to select
for larger effect size a 1.2 fold change threshold was applied. K-
means clustering (K=2) was used to separate transcripts
upregulated from transcripts down-regulated in regression condi-
tions. The proportion of false positives was estimated at 26% by
permuting 100 times the labels in each dataset prior to any gene
filtering, calculating the size of the differential profile in each
permutation, and averaging the results to determine the level of
noise. Raw data are available in GEO (accession number
GSE24819). Pathway analysis was performed using the Ingenuity
Pathway Analysis tool (MIPA) (Ingenuity Systems, Redwood City,
California) or GeneGo Metacore (GeneGo, Inc., St. Joseph,
Michigan). Enrichment for biological processes was performed as
described [18]. Briefly the genes in the differential profiles were
compared to gene families in Gene Ontology, KEGG, Swissprot
and Panther databases. P values (Fisher’s exact test) were corrected
for multiple testing (Bonferroni correction, 0.05 alpha-level).
De novo Local Causal Pathway Discovery
To discover de novo causal pathways of plaque regression and
select genes for predictive molecular signatures, we used a
multivariate gene selection technique (termed Semi-Interleaved
HITON-PC without symmetry correction). HITON-PC was
applied with Fisher’s Z-test, a=0.05 and max-k=1 [19,20]. To
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used linear support vector machine (SVM) classifiers with default
value of C=1. We used leave-one-out cross-validation (LOOCV)
approach to estimate predictive accuracy (area under ROC curve)
of molecular signatures. The statistical significance of the
produced multivariate signatures was tested with a previously
developed protocol for assessing statistical significance of multi-
variate signatures at 0.05 alpha-level [21].
Quantitative Real Time PCR (qPCR)
qPCR was used to validate specific genes of interest using 100
pg of total RNA per reaction. The primer and probe sequences are
shown in Table S1. All data were normalized to cyclophilin A or
GAPDH and expressed as fold change from the controls. Two
independent biological replicates, each one consisting of RNA
from a pool of CD68+ cells from three aortas, were used to
validate each transcript by qPCR. Data were expressed as mean 6
SEM and were analyzed by one-way ANOVA. P,0.05 was
considered significant.
Results
Normalization of dyslipidemia decreases CD68+ cell and
cholesteryl ester contents in atherosclerotic plaque
ApoE2/2 mice were fed a high fat diet for 16 weeks (‘‘baseline
mice’’) after which the aortic arches were transplanted into either
apoE2/2 (progression environment) or WT mice (regression
environment) [12]. Three days after transplantation, mice were
sacrificed, and plasma and transplanted aortic arches were
harvested. There was a 57% reduction in plaque size (Figure 1A),
and a 62% reduction in CD68+ cell content (Figure 1B) when the
recipients were WT compared to the apoE2/2 recipients. In
addition, the lipid content, most likely cholesteryl ester, decreased
significantly only under regression conditions, as measured by Oil
RedOstaining(Figure1C).Themeantotalplasmacholesterollevel
in the wild type mice was 10% of that in donor apoE2/2 mice,
whereas the mean HDL level in the WT recipients was approx-
imately three times higher than in donor apoE2/2 mice (Table 1).
Regression of atherosclerosis is associated with large-
scale change in the CD68+ macrophage transcriptome
To gain a deeper understanding of the molecular pathways
involved in plaque regression, we compared the gene expression
profiles in plaque CD68+ cells from 1) baseline apoE2/2 mice
(i.e., the aortic arch donors), 2) progressing mice (apoE2/2
donors to apoE2/2 recipients) and 3) regressing mice (apoE2/2
donors to WT recipients) using microarray technology (Figure 2A).
First, transcripts affected by the transplantation procedure rather
than by regression per se were identified as those genes that were
differentially expressed in baseline (not transplanted) vs. progres-
sion (transplanted) groups, and were removed from the analysis.
Then transcripts affected by regression were identified as those
differentially expressed in the progression vs. regression group. A
fold change of 1.2 was used as a threshold to define 1215
transcripts as the ‘‘plaque regression’’ differential profile
(Figure 2B, 2C and Table S2).
We determined which biological processes were enriched in the
plaqueregressiondifferentialprofilebycomparingthisgenesetwith
gene sets classified by biological function in the public gene set
collectionsGeneOntology,KEGG,SwissprotandPantherfamilies.
This analysis revealed that up-regulated transcripts in the plaque
regression differential profile were enriched for contractile proteins
(Tables S3 and S4). The top three biological processes enriched in
genes up-regulated in regression vs. progression were ‘‘sarcomere’’,
‘‘myofibril’’ and ‘‘muscle contraction’’. Transcripts down-regulated
in the plaque regression differential profile were enriched for
‘‘protocadherin’’ family members, which are proteins that promote
cellular adhesion, and for cell cycle/cell division gene families
(‘‘DNA metabolism’’, ‘‘histone’’, ‘‘cell cycle’’, and ‘‘DNA replica-
Figure 1. Transfer of plaques to a normolipidemic plasma
environment decreases their size and reduces their burden of
CD68+ cells and cholesteryl esters. Transplantation experiments
were performed as described in Methods. Reversal of dyslipidemia (WT
recipient) decreases plaque size (A) and CD68+ cell content (B) but
continued dyslipidemia (apoE2/2) does not. Cholesteryl ester content
was estimated by Oil Red O staining, which showed a decrease when
the recipient was a WT mouse but not an apoE2/2 mouse (C). The
symbol * corresponds to statistical significance, p,0.05, when
compared to donor apoE2/2 mice (Baseline).
doi:10.1371/journal.pone.0039790.g001
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performed qPCR. We confirmed up-regulation of several genes
associated with the contraction (titin, a-actinin, myopalladin,
myosin heavy chain, and troponin) in WT recipients (Figure 3A).
We also confirmed the down-regulation of protocadherins 4, 5, 6, 9
and 10 under regression conditions (Figure 3B).
The most highly up-regulated gene (14 fold) under regression
conditions was arginase 1. Up-regulation of this gene was validated
by qPCR (Figure 4A) and at the protein level (Figure 4C). Up-
regulation of some inflammatory markers (Cxcl2, Cxcl5 and IL1b)
was confirmed by qPCR (Figure 4B). Because arginase 1 is
considered a classical marker of the M2 (anti-inflammatory or
tissue repair) state of macrophages [22], we determined whether
other accepted M2 markers are present in the plaque regression
differential profile. We found that CD163 and C-lectin receptor
gene expression were also upregulated in the microarray results
(Table S2) and when evaluated by qPCR (Figure 4A).
Local causal pathway discovery analysis
To identify genes that may play a causal role in atherosclerotic
plaque regression, we applied a multivariate causal pathway
discovery method called HITON-PC, and then used these genes
to build multivariate molecular signatures to predict regression
and to estimate the accuracy of their predictive capability. This
approach distills a large global data set signature (based on a
univariate model, including all genes that are differentially
expressed in each experimental group) into a smaller local cause
and effect predictive signature (based on a multivariate model,
including only those genes which are directly upstream and
downstream from the response variable of interest) [19,20]. We
focused on building a multivariate molecular signature for
regression group vs. baseline and progression groups together,
since this is the most stringent comparison to reveal genes with the
potential for ‘‘driving’’ regression. This approach identified six
genes in the local causal pathway of regression, three down
regulated in the regression environment (Vcl, Tmx4, Bcl2l2) and
three upregulated (IL-9r, ApoC2 and L1cam) (Figure 5A) and
achieved very good predictive accuracy (0.838 area under the
curve (AUC) and p=0.004). We used qPCR to validate changes in
several of these factors in regression vs. progression, and Vcl,
Tmx4 and ApoC2 were validated (Figure 5B and data not shown).
Validation by protein expression for Vcl (vinculin-1) was done by
immunohistochemistry to confirm that the gene product was also
down regulated (Figure 5C).
Discussion
We have determined a molecular profile of atherosclerosis
regression in a mouse transplant model by performing microarray
analysis of plaque CD68+ cells. The profile consisted of 1215
transcripts that were differentially expressed, indicating a large
change in the transcriptome of CD68+ cells between the
regression and progression environments.
The plaque regression differential profile revealed a number of
findings: 1) genes associated with the contractile apparatus, which
plays a crucial role in cellular movement were among the most
highly up-regulated; 2) genes encoding proteins that mediate
cellular adhesion, like cadherins and vinculin, were significantly
down-regulated; 3) genes encoding histones, cell cycle, cell division
and DNA metabolism were also significantly down-regulated,
suggesting inhibition of cell division during regression; 4) during
regression macrophages display an M2-like state with increased
expression of classical markers such as arginase I, CD163 and the
C lectin receptor. The last findings led to independent studies that
Table 1. Summary of lipoprotein profile of apoE2/2 donors,
WT recipients, and apoE2/2 recipients. Values are mean 6
SD of 11 mice per group.
Groups HDL-C, mg/dL Total Cholesterol, mg/dL
apoE2/2 Donors 2163 10106203
apoE2/2 Recipients 24645 6 2 641*
WT Recipients 6969** 106612**
*P,0.05 **P,0.0001.
doi:10.1371/journal.pone.0039790.t001
Figure 2. Identification of a plaque regression differential
profile. (A) Depiction of the procedure used to determine the plaque
regression differential profile. Plaques from apoE2/2 mice on a high fat
diet were left intact (baseline) or the aortic arch (red semi circle) was
transplanted into WT (regression) or apoE2/2 (progression) mice. After
3 days, CD68+ cells were selected by Laser Capture Microdissection
(LCM), RNA was prepared, amplified, labeled and hybridized to DNA
microarray containing 23623 sequences. (B) Sequences affected by the
transplantation procedure were defined as genes that were different in
baseline (not transplanted) vs. progression (transplanted) groups
(ANOVA P.0.1) and were removed from analysis. This left 1826
sequences that were differentially expressed between progression and
regression groups (ANOVA P,0.05, in red). This set was further refined
using Resolver error model (P.0.05), which eliminates unreliable
variance estimation, and a 1.2 fold change filter, resulting in 1215
sequences that are referred to as the ‘‘plaque regression’’ differential
profile. C) Heat map of genes differentially expressed in baseline,
progression and regression. Individual aortic samples are on the Y-axis,
individual genes are on the X-axis.
doi:10.1371/journal.pone.0039790.g002
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models of regressing plaques [13,23].
The process that stimulates the elimination of CD68+ cells from
regressing plaques has not been fully defined. Our previous studies
indicate an important functional role for CCR7 in regulating
CD68+ emigration process during regression [12]. In addition, our
microarray analysis revealed further activities related to cell
emigration during regression. For example, in CD68+ cells in the
regression environment, we observed that the contractile machin-
ery is up-regulated, which would allow for the cells to migrate out
of the lesion. It is unlikely the appearance of contractile genes in
the plaque regression differential profile is due to contamination of
macrophages with smooth muscle cells, since our previous studies
have shown a large (.30 fold) and significant enrichment in
macrophage-specific transcripts relative to smooth muscle cell
mRNAs from laser captured CD68+ cells [15]. We and others
have also shown that under conditions of atherosclerosis progres-
sion, proteins such as VCAM-1 and ICAM-1 are up-regulated
[24–26]. These proteins, and the cadherins that we identified in
the present study, are cell-cell adhesion factors that help cells
maintain their location. Under regression conditions, however,
these genes are down-regulated, which would allow for the cells to
‘‘detach’’ and begin their exit from the plaque. Thus, our findings
indicate that the emigration process underlying atherosclerosis
regression reflects a complex, yet highly organized series of events
that results in decreased cellular retention and increased contrac-
tile events that together promote efficient cell migration. Part of
the complexity of cellular emigration may also be reflected by the
decrease in levels of mRNAs that encode factors involved with cell
division observed in the plaque regression differential profile,
suggesting that cell division may cease when the priority of the cell
is to migrate. Observed changes in mRNAs encoding chromatin
remodeling factors may indicate large-scale alterations in the
epigenetic control of gene expression.
There is macrophage heterogeneity in atherosclerotic plaques,
both M1 (inflammatory) and M2 (anti-inflammatory) macrophages
are detectable in lesions [27]. We observed M2 markers are up-
regulated under regression conditions. In fact, the establishment of
an anti-inflammatory state in plaque CD68+ cells during
regression appears to be a general finding [13,23]. Whether in
regressing plaques this reflects a switch from a M1 to M2
phenotype, or the replacement of M1 with M2 macrophages is
currently under investigation.
Our local causal pathway discovery analysis revealed a
molecular signature that could distinguish between the treatment
groups with high accuracy. Several genes (Vcl, Tmx4, L1cam,
Apoc2, Bcl2l2, and Il9r) were selected by HITON-PC as having a
causal role in the regression process. Vinculin-1, downregulated in
Figure 3. Regression is characterized by increasing expression
of contractile proteins and down-regulation of cadherins.
CD68+ cells were selected from plaques by LCM, RNA was isolated
and qPCR performed in order to validate microarray results. The results
of qPCR showed that the contractile proteins were up-regulated (A),
whereas members of the cadherin family were down-regulated (B). The
symbol * corresponds to statistical significance, p,0.05, when mRNA
level in the aortas from a transplanted group (apoE2/2, WT) was
compared to mRNA in aortas from donor apoE2/2 mice (Baseline). 9
mice were analyzed per group. Cyclophilin A was used for normaliza-
tion in both cases.
doi:10.1371/journal.pone.0039790.g003
Figure 4. Regression is characterized by macrophages express-
ing M2 markers. (A) qPCR analysis for RNA encoding arginase I (Arg I),
CD163 and C-lectin receptor was performed on RNA extracted from
CD68+ cells removed from plaques that were not transplanted
(baseline), plaques transplanted into apoE2/2 recipients (progression
environment) and plaques transplanted into wild type recipients (WT,
regression environment). The symbol * corresponds to statistical
significance, p,0.05, when signal in RNA from transplanted aortas
(apoE2/2, WT) was compared to signal in RNA from aortas in donor
apoE2/2 mice (Baseline). 9 mice were analyzed per group. Cyclophilin
A was used for normalization. (B), qPCR analysis for RNA encoding
Cxcl2, Cxcl5 and IL1b. The symbol * corresponds to statistical
significance, p,0.05, when signal in RNA from apoE2/2 was compared
to signal in RNA from WT mice. 9 mice were analyzed per group.
GAPDH was used for normalization. (C) Arginase I staining shows
increased protein levels in regression.
doi:10.1371/journal.pone.0039790.g004
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microfilaments to the plasma membrane [28]; Tmx4, also down-
regulated in regression, is a protein embedded in the endoplasmic
reticulum (ER) that potentially facilitates the reduction and folding
of yet to be identified client proteins [29]. ApoC2, an upregulated
gene in regression, activates lipoprotein lipase [30]. It is important
to note that ApoC2 has already been linked to HDL and
atherosclerosis [31]. This suggests that the additional factors,
although not previously linked to atherosclerosis, are potentially
important regulators of regression/progression. Future work will
further define their roles as well as the other genes in regression of
atherosclerosis.
A study in another mouse model (Reversa mice, a ‘‘genetic
switch’’ model in which hyperlipidemia can be conditionally
suppressed) [32], found that after lowering plasma lipids at 28
weeks of age, plaque progression slowed over the next 12 weeks,
but regression did not occur [33]. Under the conditions of reduced
plasma lipid levels, a 37-gene signature was identified in a
microarray analysis of aortic homogenates. Only four genes from
the Reversa study (Fndc3b, Gypc, Pvrl2 and Stat1) overlapped
with the univariate regression gene pattern reported here. This is
not surprising since in the Reversa study the lowering of plasma
lipids did not result in plaque regression. Further, unlike in the
study reported here, in the Reversa study the entire aortic wall,
containing a mixture of cell types, rather than laser captured
CD68+ cells, was used for mRNA profiling. Thus, the distinct
gene expression profiles most likely reflect discrepancies in the
extent of lipid lowering to achieve regression, and heterogeneity
among the cell types examined.
A limitation of our study is the small amount of total RNA
obtained from the laser captured CD68+ cells required a two step
amplification process. This procedure amplifies the background
noise as well as the biological signal, which is reflected in the high
rate of false positives (26%) estimated in the plaque regression
differential profile and in some discrepancies observed between
qPCR and microarrays (for example in the case of myopalladin
and some protocadherins, compare values for these genes in the
progression group, Figure 3 with Table S1). Discrepancies
between qPCR and microarrays are also seen for two genes
identified by local causal pathway discovery (Figures 5A and 5B).
Since this discovery method is based on statistical conditioning test
of independence that does not consider direction of regulation or
effect size, the errors are likely in the side of the microarrays.
Nevertheless, we validated our most informative findings by
qPCR, demonstrating that within the plaque regression differential
profile and the local causal pathway signature there is information
with significant biological relevance.
Another limitation of our study is our focus on CD68+ cells.
Although the markers indicative of specific sub-populations of
monocyte-derived cells (M1 macrophages, M2 macrophages,
immature dendritic cells, mature dendritic cells) remains open
for debate, it is commonly accepted that CD68 is a marker
expressed by all of them. Given that the bulk of monocyte-derived
cells in the plaque are macrophages and macrophage-foam cells,
we selected CD68 as a convenient criterion to use for laser
capture. We focused on macrophages, given their central role in
the pathogenesis of atherosclerosis, and the ease of isolation by
laser capture microdissection.
We are also aware that that some of the changes in gene
expression appear ‘‘counterintuitive’’ in that the levels of
‘‘inflammation-associated’’ factors are increasing rather than
decreasing and thus opposite to the overall trend of less
inflammation in the regressing plaque. There are a number of
potential reasons for this. For example, it is known that the most
efficient resolution of inflammation follows a burst of inflammation
[34]. Alternatively, because we only selected on one marker
(CD68), there could be sub-populations of monocyte-derived cells
with divergent inflammatory states. As we progress with our
research, for example, by performing FACS analyses with
macrophage specific markers of the CD68+ cells isolated from
aortic digests, these possibilities will be investigated.
In conclusion, taking advantage of a transplant model of
atherosclerosis regression we provide evidence that during
regression macrophage mRNA expression is dynamic and that
these changes may affect the inflammatory, migratory, and
metabolic properties of plaque macrophages. The insights gained
from this analysis will deepen the understanding of atherosclerosis
Figure 5. Multivariate causal pathway analysis for genes
involved in regression. (A) Heatmap displaying the relative levels
of the 6 genes selected by HITON-PC algorithm for causal relationship
to regression vs. progression/baseline task (Y-axis) in each of the 22
analyzed aortic samples (X-axis). B) RNA was isolated from laser
captured CD68+ cells. qPCR was then performed in order to validate
microarray results. The symbol * corresponds to statistical significance,
p,0.05, when signal in RNA from aortas in regression (apoE 2/2) was
compared to signal in RNA from aortas in progression (WT). 9 mice were
analyzed per group. GAPDH was used for normalization. C) Immuno-
staining for vinculin in a plaque derived from an aortic arch
transplanted from an apoE2/2 mouse into a wild type normolipidemic
mouse (apoE2/2.WT) and from an apoE2/2 mouse into a different
apoE2/2 mouse (apoE2/2.apoE2/2).
doi:10.1371/journal.pone.0039790.g005
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